Preclinical News and Research

RSS

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

FASgen, Inc. is pleased to announce that it was awarded a new $1.4 million SBIR Phase II NIH grant for continued research for obesity. FASgen has for some time had extensive research into the effects of inhibition of the fatty acid biosynthesis pathway on the regulation of appetite and weight loss.

1 Oct 2009

Social environment plays vital role in breast cancer

Social environment can play an important role in the biology of disease, including breast cancer, and lead to significant differences in health outcome, according to results of a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

1 Oct 2009

Raptor and TorreyPines Therapeutics announce merger completion

Raptor Pharmaceuticals Corp. ("Raptor") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) announced today the completion of their merger.

1 Oct 2009

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Ardea Biosciences, Inc. announced that it will present results from a Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the 2009 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

1 Oct 2009

Amicus Therapeutics to initiate Phase 1 study of AT2220

Amicus Therapeutics today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease.

30 Sep 2009

Parathyroid gland transplants may prevent untreatable form of bone loss

An early laboratory success is taking University of Michigan researchers a step closer to parathyroid gland transplants that could one day prevent a currently untreatable form of bone loss associated with thyroid surgery.

30 Sep 2009

Reuters examines how HIV vaccine trial results will guide future studies

Reuters reports on how the results of an experimental AIDS vaccine, which showed modest potential for preventing infection, are leading researchers back "to the drawing board" as they try to better understand how the AIDS vaccine works.

30 Sep 2009

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical study of its novel heat shock protein 90 (Hsp90) inhibitor, STA-9090 in hematologic malignancies with a once-a-week dosing schedule.

29 Sep 2009

Ligand and GSK amend agreement to pursue independent research programs

Ligand Pharmaceuticals Incorporated today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline, GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would otherwise have been required upon the identification of a new lead chemical series for advancement in its alliance with GSK.

29 Sep 2009

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.

28 Sep 2009

Preclinical data of CardiAQ Valve Technologies' TMVI in vivo study presented at the TCT 2009

Transcatheter heart valve company CardiAQ Valve Technologies (CVT), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that successful results of an acute in vivo study of its TMVI system were disclosed by Dr. Joseph Bavaria during the “Mitral Valve Therapies Prior to and in Human Investigation” program at the “Transcatheter Cardiovascular Therapeutics (TCT) 2009” annual scientific meeting on Friday.

28 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

Central metabolic network model of Thermotoga maritima bacterium developed

Investigators at Burnham Institute for Medical Research (Burnham), University of California, San Diego (UC San Diego), The Scripps Research Institute (TSRI), Genomics Institute of the Novartis Research Foundation (GNF) and other institutions have constructed a complete model, including three dimensional protein structures, of the central metabolic network of the bacterium Thermotoga maritima (T. maritima).

25 Sep 2009

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it has recently acquired direct ownership of technology for which it had previously exercised its option to exclusively license from Advirna LLC.

25 Sep 2009

CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanoma

Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.

24 Sep 2009

Pre-clinical data demonstrates advantages of Combo Stent

OrbusNeich announced today that pre-clinical data involving porcine coronary models demonstrate that the company's Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) may offer advantages to the Cypher(R) sirolimus eluting stent and the XIENCE(TM) V everolimus eluting stent.

24 Sep 2009

New version of Adis R&D Insight global pipeline database launched

Wolters Kluwer Pharma Solutions, Inc., a leading provider of market data and competitive intelligence to the pharmaceutical and biotech industries, today introduced a powerful, new version of its popular Adis R&D Insight global pipeline database.

24 Sep 2009

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class therapy for dry eye, LX214 (topical mixed nanomicellar formulation of voclosporin).

24 Sep 2009

VisEn launches new imaging agent for monitoring key hypertension and renal disease biomarker

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new ReninSense680(TM) FAST imaging agent for measuring and monitoring a key hypertension and renal disease biomarker in vivo.

24 Sep 2009

Titanium dioxide nanoparticles catalyze brain tumor death

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago Medical Center's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to antibodies.

23 Sep 2009

Preclinical News and Research

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

Social environment plays vital role in breast cancer

Raptor and TorreyPines Therapeutics announce merger completion

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Amicus Therapeutics to initiate Phase 1 study of AT2220

Parathyroid gland transplants may prevent untreatable form of bone loss

Reuters examines how HIV vaccine trial results will guide future studies

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Ligand and GSK amend agreement to pursue independent research programs

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

Preclinical data of CardiAQ Valve Technologies' TMVI in vivo study presented at the TCT 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Central metabolic network model of Thermotoga maritima bacterium developed

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanoma

Pre-clinical data demonstrates advantages of Combo Stent

New version of Adis R&D Insight global pipeline database launched

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

VisEn launches new imaging agent for monitoring key hypertension and renal disease biomarker

Titanium dioxide nanoparticles catalyze brain tumor death

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News